Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT00116142 Completed - Prostate Cancer Clinical Trials

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Start date: June 2005
Phase: Phase 3
Study type: Interventional

This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer.

NCT ID: NCT00115635 Completed - Prostate Cancer Clinical Trials

Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

Start date: March 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the study is to determine the optimal dose of the combination of docetaxel and gemcitabine in patients with hormone refractory prostate cancer, and evaluate this dose with respect to efficacy and toxicity in a phase II trial.

NCT ID: NCT00114985 Completed - Prostate Cancer Clinical Trials

Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal Bleeding

Start date: April 2001
Phase: Phase 2
Study type: Interventional

During 3D-conformal external beam radiation therapy treatments for prostate cancer, the prostate gland moves. The purpose of this study is to determine whether the placement of a prostate immobilization device into the rectum during radiation treatments will decrease the risk of rectal bleeding that is sometimes seen as a late effect from radiation.

NCT ID: NCT00111618 Completed - Prostate Cancer Clinical Trials

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

Start date: May 2005
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to confirm a safe dose of AS1404, to be given with docetaxel, and to see whether adding AS1404 and docetaxel together improves the outcome of the treatment, when compared to docetaxel alone.

NCT ID: NCT00110188 Completed - Prostate Cancer Clinical Trials

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Start date: May 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the antitumor activity of weekly ridaforolimus study treatment in participants with taxane-resistant AIPC.

NCT ID: NCT00110162 Recruiting - Prostate Cancer Clinical Trials

Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

Start date: October 2004
Phase: Phase 3
Study type: Interventional

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. PURPOSE: This randomized phase III trial is studying how well androgen deprivation therapy works in treating patients with prostate cancer.

NCT ID: NCT00108290 Completed - Prostate Cancer Clinical Trials

Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer

Start date: April 2004
Phase: Phase 2
Study type: Interventional

In men with prostate cancer who do not have evidence of spread to bone or other sites on computed axial tomography (CAT) scan/bone scan but are still at significant risk of failing treatment with surgery or radiation alone, a combination of chemotherapy and hormone therapy is being given for 6 months followed by surgery to remove the prostate.

NCT ID: NCT00108264 Completed - Prostate Cancer Clinical Trials

Tumor RNA Transfected Dendritic Cell Vaccines

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to use dendritic cells transfected with amplified RNA from autologous tumor cells to develop a vaccine strategy for the treatment of prostate cancer in patients with disseminated disease.

NCT ID: NCT00106418 Completed - Prostate Cancer Clinical Trials

A Research Study for Patients With Prostate Cancer

Start date: May 7, 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the activity of romidepsin (depsipeptide,FK228) in patients with metastatic prostate cancer who have developed a rising prostate specific antigen (PSA) while undergoing hormonal therapy.

NCT ID: NCT00106392 Completed - Prostate Cancer Clinical Trials

A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy

Start date: February 2005
Phase: Phase 4
Study type: Interventional

The purpose of the study is to compare the safety and effectiveness of Prograf in the prevention of erectile dysfunction in men after a radical prostatectomy.